RxDoctor Payments Data

Jill Kane, DO

Emergency Medicine · Levittown, PANPI 1124021431

Payments from drug & device makers

$1,136in general payments, 2019–2025

Across 61 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$165
  • Lilly USA, LLC$151
  • Boehringer Ingelheim$147
  • Novo Nordisk$130
  • Bayer$67
  • Astellas Pharma US Inc$61
  • plus $414 from 13 others

What the payments were for

  • Food & beverage$1,136100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,136 in reported general payments places this provider in the 95th percentile of 3,120 emergency medicine providers in Pennsylvania.

See all emergency medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$83,957
Medicare patients
427
Services billed
609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$54,475
EliquisApixaban15$17,903
ArexvyRsvpref3 Antigen/As01e/Pf28$8,174
LinzessLinaclotide14$8,037
ShingrixVaricella-Zoster Ge/As01b/Pf18$3,772
Divalproex Sodium13$2,617
Valsartan39$2,428
Atorvastatin Calcium123$1,407
Albuterol Sulfate HfaAlbuterol Sulfate41$1,126
Pantoprazole Sodium71$1,108
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide22$930
Metoprolol Succinate47$825
Levothyroxine Sodium56$800
Fluticasone Propionate45$593
Pravastatin Sodium24$567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$130$54,47541 claims
PfizerEliquis$50$17,90315 claims
GSKArexvy, Shingrix$30$11,94646 claims
AbbVieLinzess$165$8,03714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,120 emergency medicine providers in Pennsylvania.

Other emergency medicine in Levittown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →